Ascendis Pharma A/S filed a Form 6-K on November 12, 2026, containing unaudited condensed consolidated interim financial statements and management's discussion and analysis for the three and nine months ended September 30, 2026.

Key Highlights

  • Revenue surge: Revenue for the nine months ended September 30, 2026 reached EUR 955,543 thousand, compared with EUR 472,632 thousand for the same period in 2025, according to the filing.
  • Net profit swing: The company reported a net profit of EUR 910,283 thousand for the nine-month period, versus a net loss of EUR 194,472 thousand in the prior-year period.
  • Q3 2026 performance: For the three months ended September 30, 2026, the company reported revenue of EUR 369,657 thousand and a net profit of EUR 73,973 thousand.
  • Deferred tax asset recognized: Total deferred tax assets of EUR 651,891 thousand were recorded as of September 30, 2026, compared with zero as of December 31, 2025.
  • Equity turnaround: Total equity as of September 30, 2026 was EUR 1,500,451 thousand, compared with negative EUR 162,821 thousand as of December 31, 2025.
  • Convertible notes redeemed: The filing shows a capital increase from redemption of convertible notes of EUR 719,518 thousand during the nine-month period, with no convertible notes outstanding as of September 30, 2026.
  • Operating cash flows: Cash flows from operating activities for the nine months ended September 30, 2026 were EUR 462,754 thousand, compared with negative EUR 19,501 thousand in the same period of 2025.

Ascendis Pharma Financial Results: Nine Months Ended September 30, 2026

According to the Form 6-K filed with the U.S. Securities and Exchange Commission, Ascendis Pharma A/S (NASDAQ:ASND), a Danish biopharmaceutical company headquartered in Hellerup, Denmark, reported substantial year-over-year improvement across its key financial metrics for the nine months ended September 30, 2026. The company disclosed revenue of EUR 955,543 thousand for the period, more than double the EUR 472,632 thousand recorded for the nine months ended September 30, 2025. Gross profit for the nine-month period was EUR 882,059 thousand, compared with EUR 401,315 thousand in the prior-year period.

The filing disclosed operating profit of EUR 369,853 thousand for the nine months ended September 30, 2026, which included other operating income of EUR 158,067 thousand recorded in the period. This compares with an operating loss of EUR 146,167 thousand for the nine months ended September 30, 2025. Income tax for the nine-month 2026 period reflected a benefit of EUR 614,995 thousand, in contrast to an expense of EUR 8,526 thousand in the prior-year period. The filing attributes a deferred tax asset of EUR 651,891 thousand on the September 30, 2026 balance sheet, where none existed at December 31, 2025. Basic earnings per share for the nine months ended September 30, 2026 were EUR 14.24, compared with a loss per share of EUR 3.22 for the same period in 2025.

The company's balance sheet as of September 30, 2026 showed total assets of EUR 2,427,184 thousand and cash and cash equivalents of EUR 964,364 thousand, up from EUR 616,041 thousand at December 31, 2025. The convertible notes that carried a combined balance of EUR 685,622 thousand (borrowings of EUR 429,391 thousand and derivative liabilities of EUR 256,231 thousand) at December 31, 2025 were fully extinguished by September 30, 2026, according to the filing. The company also disclosed that it repurchased treasury shares resulting in an outflow of EUR 161,321 thousand during the nine-month period.

What Was Disclosed

Ascendis Pharma A/S filed unaudited interim financial statements covering the three and nine months ended September 30, 2026, reporting revenue of EUR 955,543 thousand, a net profit of EUR 910,283 thousand, and a substantial improvement in total equity for the nine-month period.